---
title: UK pharma media reputation tracker – August 2026
canonical_url: https://www.omniscan.ai/benchmarks/uk-pharma-2026-08
type: dataset
publisher: Omniscan
sector: Pharma in the UK
period: August 2026
coverage_start: '2026-08-01'
coverage_end: '2026-08-31'
date_published: '2026-09-01'
last_updated: '2026-09-01'
organisations: 10
articles_analysed: 886
mentions: 898
data_download: https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/data.json
summary: AstraZeneca had the highest average monthly share of coverage (35.0%) among
  10 companies in UK earned media from 1 August 2026 to 31 August 2026, ahead of Eli
  Lilly (25.1%) and Novo Nordisk (18.8%).
---

# UK pharma media reputation tracker: August 2026 (1 August 2026–31 August 2026)

> AstraZeneca had the highest average monthly share of coverage (35.0%) among 10 companies in UK earned media from 1 August 2026 to 31 August 2026, ahead of Eli Lilly (25.1%) and Novo Nordisk (18.8%). Novartis had the most favourable net tone (+92). Omniscan analysed 886 articles containing 898 mentions of the companies tracked.

Interactive version: https://www.omniscan.ai/benchmarks/uk-pharma-2026-08

## Pharma in the UK ranking by share of coverage, August 2026

| Rank | Organisation | Average monthly share of coverage | Mentions | Positive | Neutral | Negative | Net tone |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | AstraZeneca | 35.0% | 314 | 19% | 61% | 20% | −1 |
| 2 | Eli Lilly | 25.1% | 225 | 69% | 21% | 10% | +60 |
| 3 | Novo Nordisk | 18.8% | 169 | 17% | 73% | 10% | +7 |
| 4 | GSK | 8.6% | 77 | 36% | 57% | 7% | +30 |
| 5 | MSD | 3.3% | 30 | 70% | 23% | 7% | +63 |
| 5 | Moderna | 3.3% | 30 | 90% | 10% | 0% | +90 |
| 7 | Pfizer | 1.8% | 16 | 25% | 38% | 37% | −12 |
| 8 | Roche | 1.4% | 13 | 69% | 31% | 0% | +69 |
| 9 | Novartis | 1.3% | 12 | 92% | 8% | 0% | +92 |
| 9 | Sanofi | 1.3% | 12 | 0% | 58% | 42% | −42 |

## Companies in detail

### AstraZeneca

**M&A & Licensing shaped AstraZeneca's media profile during August 2026**

AstraZeneca ranked 1st of 10 by average monthly share of coverage (35.0%) in the Pharma in the UK benchmark for August 2026, with 314 mentions and a net tone of −1.

August extended the lead to 35.0%, with extensive reporting on possible Bristol Myers Squibb merger talks, their subsequent denial and the halted volrustomig trial. August 2026: preliminary AstraZeneca–Bristol Myers Squibb tie-up discussions were reported by Bloomberg. AstraZeneca and Amgen said Tezspire met all main Phase 3 trial objectives in eosinophilic esophagitis, potentially supporting a third indication. The expansion could support AstraZeneca's longer-term sales strategy and compete with Sanofi's Dupixent. The article names UK-listed AstraZeneca as a FTSE 100 growth stock, citing pipeline momentum and positive Phase 3 Tezspire data. It reports predominantly positive broker ratings and a consensus target price implying around 32% upside. AstraZeneca priced a €2.55 billion multi-tranche Eurobond offering under its Euro Medium Term Note programme, with notes to be listed in London. Proceeds are intended for general corporate purposes and long-term funding management.

Key messages:

- AstraZeneca and Amgen said Tezspire met all main Phase 3 trial objectives in eosinophilic esophagitis, potentially supporting a third indication. The expansion could support AstraZeneca's longer-term sales strategy and compete with Sanofi's Dupixent.
- The article names UK-listed AstraZeneca as a FTSE 100 growth stock, citing pipeline momentum and positive Phase 3 Tezspire data. It reports predominantly positive broker ratings and a consensus target price implying around 32% upside.
- AstraZeneca priced a €2.55 billion multi-tranche Eurobond offering under its Euro Medium Term Note programme, with notes to be listed in London. Proceeds are intended for general corporate purposes and long-term funding management.
- The article considers whether AstraZeneca represents value despite speculation over a possible takeover of another major pharmaceutical company. It highlights chief executive Pascal Soriot’s reputation and questions the strategic logic of a mega-merger.
- AstraZeneca is among more than 100 UK companies eligible to use an expanded fast-track Global Talent Visa route for researchers. The policy is intended to help businesses recruit highly skilled staff.

Leading themes:

- M&A & Licensing: 50.3% of AstraZeneca's coverage (theme index 12.78, net tone −23)
- Clinical Trials & Research: 23.2% of AstraZeneca's coverage (theme index 1.97, net tone +22)
- Financial Results & Pipeline: 13.4% of AstraZeneca's coverage (theme index 1.3, net tone +29)

Notable positive coverage:

- 27 August 2026, biopharmadive.com: [New data could widen use of AstraZeneca, Amgen immune disease drug](https://www.biopharmadive.com/news/astrazeneca-amgen-tezpire-eosinophilic-esophagitis-results/828946/). AstraZeneca and Amgen said Tezspire met all main Phase 3 trial objectives in eosinophilic esophagitis, potentially supporting a third indication. The expansion could support AstraZeneca's longer-term sales strategy and compete with Sanofi's Dupixent.
- 31 August 2026, uk.finance.yahoo.com: [Here are 2 FTSE 100 growth stocks tipped to deliver 30%+ gains in the coming 12 months](https://uk.finance.yahoo.com/news/2-ftse-100-growth-stocks-060000722.html). The article names UK-listed AstraZeneca as a FTSE 100 growth stock, citing pipeline momentum and positive Phase 3 Tezspire data. It reports predominantly positive broker ratings and a consensus target price implying around 32% upside.
- 26 August 2026, theglobeandmail.com: [AstraZeneca Prices €2.55 Billion Eurobond to Support Long-Term Funding Strategy](https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4070177/astrazeneca-prices-eur2-55-billion-eurobond-to-support-long-term-funding-strategy/). AstraZeneca priced a €2.55 billion multi-tranche Eurobond offering under its Euro Medium Term Note programme, with notes to be listed in London. Proceeds are intended for general corporate purposes and long-term funding management.

Notable negative coverage:

- 3 August 2026, standard.co.uk: [AstraZeneca in talks over £300bn mega-merger with US rival – reports](https://www.standard.co.uk/business/business-news/astrazeneca-financial-times-new-york-cambridge-trump-b1292148.html). AstraZeneca has reportedly held talks with Bristol Myers Squibb about a merger worth more than £300 billion. Its shares fell following the reports, while analysts flagged oncology overlap, regulatory barriers and potential implications for its UK status.
- 3 August 2026, marketwatch.com: [AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.](https://www.marketwatch.com/story/astrazeneca-tie-up-talks-with-bristol-myers-squibb-are-moving-stocks-analysts-are-puzzled-7ae60fef). AstraZeneca shares fell after reports of early-stage tie-up talks with Bristol Myers Squibb. The potential transaction would rank among the largest pharmaceutical deals.
- 3 August 2026, fiercepharma.com: [Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea](https://www.fiercepharma.com/pharma/astrazeneca-bristol-myers-squibb-merger-would-be-bad-idea). An editorial argues that a proposed AstraZeneca-Bristol Myers Squibb merger would be strategically damaging, risking antitrust intervention, pipeline disruption and job losses. It says AstraZeneca can instead build its US presence organically and pursue targeted deals.

- [AstraZeneca deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=astrazeneca&view=deep-dive)
- [AstraZeneca PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/astrazeneca.pdf)

### Eli Lilly

**Lilly rebounded to second place as Foundayo launched in the UK**

Eli Lilly ranked 2nd of 10 by average monthly share of coverage (25.1%) in the Pharma in the UK benchmark for August 2026, with 225 mentions and a net tone of +60.

August brought the largest monthly volume, at 225 mentions, and a recovery to second place with a 25.1% share. Across the window, Lilly’s independent editorial profile shifted from sustained Mounjaro safety and access scrutiny towards a broader mix of pipeline, acquisition, delivery and regulatory developments, culminating in an approvals-led August. August 2026: volume increased by 128 and share rose 13.4 points to 25.1%, moving Lilly from fourth to second; contemporaneous coverage centred on Foundayo’s UK approval and launch. August 2026: The Wall Street Journal reported Foundayo’s launch in the UK, its first European market. Eli Lilly has launched Foundayo for weight management and type 2 diabetes in the UK through private prescription after MHRA authorisation. NICE must assess the medicine before NHS availability, and the article compares its private price with Lilly's Mounjaro and Novo Nordisk's Wegovy.

Key messages:

- Eli Lilly has launched Foundayo for weight management and type 2 diabetes in the UK through private prescription after MHRA authorisation. NICE must assess the medicine before NHS availability, and the article compares its private price with Lilly's Mounjaro and Novo Nordisk's Wegovy.
- TV presenter Narinder Kaur reported severe hair loss and anxiety while using Eli Lilly's Mounjaro, with her clinician saying hair loss can occur during treatment and may be temporary. Lilly said its patient leaflet identifies hair loss as a common side effect in weight-management patients and urged medically supervised use.
- An East London inquest heard that a 19-year-old student who had been prescribed tirzepatide died after nausea and vomiting, with an underlying congenital heart condition potentially increasing risk. Tirzepatide is sold as Mounjaro in the UK.
- MHRA Yellow Card data show more than 200 reported deaths suspected to be linked to GLP-1 weight-loss and diabetes medicines in the UK, including tirzepatide and semaglutide products. The regulator stresses that reports do not establish causation and that the benefits outweigh risks when medicines are used as authorised.
- An inquest is examining whether a Norfolk woman's death after increasing her Mounjaro dose was connected to the medicine or to shortcomings in her hospital assessment. The hearing noted gastrointestinal side effects are known, but said there is no established evidence that Mounjaro causes intestinal perforation.

Leading themes:

- Drug Approvals & Launches: 48.0% of Eli Lilly's coverage (theme index 3.3, net tone +97)
- Medicines Safety, Supply & Patient Use: 27.6% of Eli Lilly's coverage (theme index 4.76, net tone −10)
- NHS Access & Pricing: 8.0% of Eli Lilly's coverage (theme index 2.83, net tone +72)

Notable positive coverage:

- 24 August 2026, rte.ie: [Eli Lilly launches oral weight-loss drug Foundayo in UK](https://www.rte.ie/news/business/2026/0824/1588999-eli-lilly-launches-oral-weight-loss-drug-foundayo-in-uk/). Eli Lilly has launched Foundayo for weight management and type 2 diabetes in the UK through private prescription after MHRA authorisation. NICE must assess the medicine before NHS availability, and the article compares its private price with Lilly's Mounjaro and Novo Nordisk's Wegovy.
- 24 August 2026, reuters.com: [Eli Lilly launches oral weight-loss pill Foundayo in UK](https://www.reuters.com/legal/litigation/eli-lilly-launches-oral-weight-loss-pill-foundayo-uk-2026-08-23/). Eli Lilly has launched its oral weight-management and type 2 diabetes pill, Foundayo, in the UK. The UK is the first European country in which the treatment is available.
- 24 August 2026, wsj.com: [Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.](https://www.wsj.com/health/pharma/eli-lilly-launches-foundayo-weight-loss-pill-in-u-k-442845f4). Eli Lilly has launched its Foundayo oral weight-loss treatment in the UK, described as the first European market to offer it.

Notable negative coverage:

- 18 August 2026, mirror.co.uk: [Narinder Kaur left 'panicking' over severe hair loss after starting Mounjaro](https://www.mirror.co.uk/3am/celebrity-news/narinder-kaur-hair-loss-mounjaro-37560691). TV presenter Narinder Kaur reported severe hair loss and anxiety while using Eli Lilly's Mounjaro, with her clinician saying hair loss can occur during treatment and may be temporary. Lilly said its patient leaflet identifies hair loss as a common side effect in weight-management patients and urged medically supervised use.
- 12 August 2026, ladbible.com: [Death of law student, 19, linked to weight-loss jab as tragic symptoms shared](https://www.ladbible.com/news/uk-news/student-dies-university-weight-loss-drugs-788730-20260812). An East London inquest heard that a 19-year-old student who had been prescribed tirzepatide died after nausea and vomiting, with an underlying congenital heart condition potentially increasing risk. Tirzepatide is sold as Mounjaro in the UK.
- 11 August 2026, independent.co.uk: [London law student died after taking weight loss drug, inquest told](https://www.independent.co.uk/news/uk/home-news/josephine-nasr-inquest-tirzepatide-mounjaro-overdose-b3030938.html). A London inquest concluded that prescribed tirzepatide contributed to a student's fatal electrolyte imbalance and cardiac arrhythmia, alongside an underlying congenital heart condition. Tirzepatide is sold as Mounjaro in the UK and Zepbound in the US.

- [Eli Lilly deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=elililly&view=deep-dive)
- [Eli Lilly PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/elililly.pdf)

### Novo Nordisk

**Novo Nordisk’s Wegovy expansion meets a broader pipeline test**

Novo Nordisk ranked 3rd of 10 by average monthly share of coverage (18.8%) in the Pharma in the UK benchmark for August 2026, with 169 mentions and a net tone of +7.

In August 2026, Novo Nordisk recorded 169 mentions, 18.8% of cohort coverage and rank #3, with net sentiment of +7. Coverage focused on Drug Approvals & Launches. August 2026: share rose two points to 18.8% and volume increased by 29, with the company remaining third; stories included the AWS London research hub and questions about pipeline renewal. August 2026: PharmaTimes reported Novo Nordisk’s AWS partnership and London hub for drug discovery and clinical development. A UK patient describes losing 12lb in six weeks after using Novo Nordisk's oral Wegovy, which is available privately through UK pharmacies but not yet on the NHS. She reports no side effects and says the tablet suited her because she is afraid of injections. Morningstar reduced its fair-value estimate for Novo Nordisk after its second-quarter earnings, citing expected margin pressure, generic semaglutide competition and disappointing cagrisema trial results. The article notes that Wegovy pill launches in the UK and US have achieved strong volumes, while competition from Eli Lilly remains significant.

Key messages:

- A UK patient describes losing 12lb in six weeks after using Novo Nordisk's oral Wegovy, which is available privately through UK pharmacies but not yet on the NHS. She reports no side effects and says the tablet suited her because she is afraid of injections.
- Morningstar reduced its fair-value estimate for Novo Nordisk after its second-quarter earnings, citing expected margin pressure, generic semaglutide competition and disappointing cagrisema trial results. The article notes that Wegovy pill launches in the UK and US have achieved strong volumes, while competition from Eli Lilly remains significant.
- Novo Nordisk has begun a US trial testing lower doses of its Wegovy weight-loss pill. The medicine has also become available in the UK as the company seeks to regain obesity-market share.
- Novo Nordisk and Amazon Web Services have established an AI research hub at Novo Nordisk’s London facility to accelerate drug discovery and development. The partnership makes AWS Novo Nordisk’s preferred cloud provider and is intended to improve research and operational productivity.
- Novo Nordisk discussed the difficulty of finding new growth drugs after a phase III failure for cardiovascular candidate ziltivekimab, alongside weaker share performance and past job cuts. The article also covers its Wegovy pill rollout in Europe and the UK, competition from Eli Lilly, and speculation about a potential AstraZeneca-Bristol Myers Squibb merger.

Leading themes:

- Drug Approvals & Launches: 47.3% of Novo Nordisk's coverage (theme index 2.74, net tone +6)
- Medicines Safety, Supply & Patient Use: 20.1% of Novo Nordisk's coverage (theme index 2.19, net tone −18)
- Financial Results & Pipeline: 10.7% of Novo Nordisk's coverage (theme index 0.92, net tone +17)

Notable positive coverage:

- 31 August 2026, mirror.co.uk: ['I was one of first on Wegovy pill - the effects have been big'](https://www.mirror.co.uk/news/health/i-one-first-wegovy-weight-37598639). A UK patient describes losing 12lb in six weeks after using Novo Nordisk's oral Wegovy, which is available privately through UK pharmacies but not yet on the NHS. She reports no side effects and says the tablet suited her because she is afraid of injections.
- 4 August 2026, qz.com: [Novo Nordisk Q2 2026 earnings beat, raises full-year outlook](https://qz.com/novo-nordisk-earnings-wegovy-pill-full-year-outlook-080426). Novo Nordisk raised its 2026 outlook after second-quarter adjusted operating profit exceeded expectations, supported by Wegovy pill demand. The article notes that the pill launched in the UK in August and that the higher-dose Wegovy pen is available in the UK.
- 19 August 2026, morningstar.com: [Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills](https://www.morningstar.com/news/dow-jones/202608195205/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills). Novo Nordisk has begun a US trial testing lower doses of its Wegovy weight-loss pill. The medicine has also become available in the UK as the company seeks to regain obesity-market share.

Notable negative coverage:

- 6 August 2026, fortune.com: [Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult](https://fortune.com/2026/08/06/weight-loss-drug-wegovy-novo-nordisk-europe-most-valuable-company-blockbuster-drug/). Novo Nordisk discussed the difficulty of finding new growth drugs after a phase III failure for cardiovascular candidate ziltivekimab, alongside weaker share performance and past job cuts. The article also covers its Wegovy pill rollout in Europe and the UK, competition from Eli Lilly, and speculation about a potential AstraZeneca-Bristol Myers Squibb merger.
- 28 August 2026, medwatch.com: [Novo Nordisk and Eli Lilly intensify the battle against generics in the UK](https://medwatch.com/News/Pharma___Biotech/article19589120.ece). Novo Nordisk and Eli Lilly are intensifying action against illegal and unregulated weight-loss injections in the UK. The article says British authorities are seizing large quantities as high prices and restricted access drive patients toward unregulated products.
- 6 August 2026, global.morningstar.com: [Novo Nordisk: What We Think of the Stock After Earnings](https://global.morningstar.com/en-gb/stocks/novo-nordisk-what-we-think-stock-after-earnings). Morningstar reduced its fair-value estimate for Novo Nordisk after its second-quarter earnings, citing expected margin pressure, generic semaglutide competition and disappointing cagrisema trial results. The article notes that Wegovy pill launches in the UK and US have achieved strong volumes, while competition from Eli Lilly remains significant.

- [Novo Nordisk deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=novonordisk&view=deep-dive)
- [Novo Nordisk PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/novonordisk.pdf)

### GSK

**Financial Results & Pipeline shaped GSK's media profile during August 2026**

GSK ranked 4th of 10 by average monthly share of coverage (8.6%) in the Pharma in the UK benchmark for August 2026, with 77 mentions and a net tone of +30.

August then brought a 15.1-point fall to 8.6% and fourth place, as the agenda narrowed towards pipeline assessments, investment analysis, Shingrix research and the consequences of the Stevenage relocation. August 2026: volume fell by 120 and share dropped 15.1 points to 8.6%, returning GSK to fourth; contemporaneous coverage examined the Stevenage relocation and GSK’s Phase III pipeline. The article examines additional health benefits associated with several vaccines, including evidence that Shingrix may reduce cardiovascular events. It also discusses the wider preventive effects of MMR, BCG and HPV vaccination, including UK HPV outcomes. An Oxford-led study found Shingrix was associated with a lower risk of cardiovascular events in US health-record data. The article notes that the vaccine is offered in the UK to people over 65 and that clinical trials are needed to confirm the effect.

Key messages:

- The article examines additional health benefits associated with several vaccines, including evidence that Shingrix may reduce cardiovascular events. It also discusses the wider preventive effects of MMR, BCG and HPV vaccination, including UK HPV outcomes.
- An Oxford-led study found Shingrix was associated with a lower risk of cardiovascular events in US health-record data. The article notes that the vaccine is offered in the UK to people over 65 and that clinical trials are needed to confirm the effect.
- Barclays maintained a Sell rating and a £19 price target for GSK. The article cites quarterly revenue growth but lower net profit and negative insider-selling sentiment.
- GSK is moving most of its Stevenage research workforce to Cambridge, raising concerns over the impact on Stevenage, where its campus has been a major employer. The article focuses on the local economic and workforce consequences of the relocation.
- GSK’s decision to move its research hub from Stevenage to Cambridge is presented as a threat to Stevenage’s biotech ecosystem and local economy. The article characterises the departure as a significant blow to the town’s science ambitions.

Leading themes:

- Financial Results & Pipeline: 29.9% of GSK's coverage (theme index 3.1, net tone +13)
- Leadership & Strategy: 28.6% of GSK's coverage (theme index 5.21, net tone +9)
- Vaccines & Public Health: 10.4% of GSK's coverage (theme index 6.56, net tone +88)

Notable positive coverage:

- 27 August 2026, inews.co.uk: [The surprise bonus benefits of four common vaccines](https://inews.co.uk/news/surprise-bonus-benefits-four-common-vaccines-4728912). The article examines additional health benefits associated with several vaccines, including evidence that Shingrix may reduce cardiovascular events. It also discusses the wider preventive effects of MMR, BCG and HPV vaccination, including UK HPV outcomes.
- 26 August 2026, theguardian.com: [Shingles vaccine linked to lower risk of heart attack and stroke, study finds](https://www.theguardian.com/science/2026/aug/26/shingles-vaccine-lower-risk-heart-attack-stroke-study). An Oxford-led study found Shingrix was associated with a lower risk of cardiovascular events in US health-record data. The article notes that the vaccine is offered in the UK to people over 65 and that clinical trials are needed to confirm the effect.
- 26 August 2026, independent.co.uk: [NHS shingles jab could lower risk of stroke and heart attacks](https://www.independent.co.uk/life-style/health-and-families/health-news/nhs-shingles-vaccine-shingrix-symptoms-b3039443.html). Oxford research found that people receiving GSK's Shingrix shingles vaccine had longer cardiovascular-disease-free survival than those receiving Zostavax. The article notes Shingrix is offered through the NHS to eligible groups.

Notable negative coverage:

- 26 August 2026, theglobeandmail.com: [Barclays Sticks to Their Sell Rating for GlaxoSmithKline (GSK)](https://www.theglobeandmail.com/investing/markets/stocks/GSK/pressreleases/4071469/barclays-sticks-to-their-sell-rating-for-glaxosmithkline-gsk/). Barclays maintained a Sell rating and a £19 price target for GSK. The article cites quarterly revenue growth but lower net profit and negative insider-selling sentiment.
- 21 August 2026, bloomberg.com: [Stevenage Braces for Life After GSK as Drugmaker Moves to Cambridge](https://www.bloomberg.com/news/articles/2026-08-21/stevenage-braces-for-life-after-gsk-as-drugmaker-moves-to-cambridge). GSK is moving most of its Stevenage research workforce to Cambridge, raising concerns over the impact on Stevenage, where its campus has been a major employer. The article focuses on the local economic and workforce consequences of the relocation.
- 18 August 2026, thetimes.com: [Stevenage’s biotech dream is in jeopardy after GSK exodus](https://www.thetimes.com/business/companies-markets/article/stevenages-biotech-dream-is-in-jeopardy-after-gsk-exodus-pzt8lv39d). GSK’s decision to move its research hub from Stevenage to Cambridge is presented as a threat to Stevenage’s biotech ecosystem and local economy. The article characterises the departure as a significant blow to the town’s science ambitions.

- [GSK deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=gsk&view=deep-dive)
- [GSK PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/gsk.pdf)

### MSD

**MSD coverage shifted from NHS access to clinical research**

MSD ranked 5th of 10 by average monthly share of coverage (3.3%) in the Pharma in the UK benchmark for August 2026, with 30 mentions and a net tone of +63.

In August 2026, MSD recorded 30 mentions, 3.3% of cohort coverage and rank #5, with net sentiment of +63. Coverage focused on Clinical Trials & Research. Interim phase-three results suggest that personalised melanoma vaccine intismeran, developed by MSD and Moderna and used with Keytruda, extends cancer-free time. NHS England is preparing for potential adoption pending trial completion, regulatory approval and further NHS assessment. AstraZeneca terminated the phase III eVOLVE-Lung02 trial after Volrustomig plus chemotherapy was unlikely to outperform Keytruda. It also reported encouraging late-stage results for Enhertu and Tagrisso-Orpathys, while MSD's Keytruda is discussed as the comparator and leading immuno-oncology medicine. Moderna and Merck reported that their personalised mRNA cancer vaccine plus Keytruda met key phase III endpoints in resected high-risk melanoma. UK experts said the findings reinforce the UK's position as a major environment for cancer-vaccine clinical trials.

Key messages:

- Interim phase-three results suggest that personalised melanoma vaccine intismeran, developed by MSD and Moderna and used with Keytruda, extends cancer-free time. NHS England is preparing for potential adoption pending trial completion, regulatory approval and further NHS assessment.
- AstraZeneca terminated the phase III eVOLVE-Lung02 trial after Volrustomig plus chemotherapy was unlikely to outperform Keytruda. It also reported encouraging late-stage results for Enhertu and Tagrisso-Orpathys, while MSD's Keytruda is discussed as the comparator and leading immuno-oncology medicine.
- Moderna and Merck reported that their personalised mRNA cancer vaccine plus Keytruda met key phase III endpoints in resected high-risk melanoma. UK experts said the findings reinforce the UK's position as a major environment for cancer-vaccine clinical trials.
- NICE has issued a positive recommendation for Eli Lilly's once-weekly insulin Onswik, subject to MHRA marketing authorisation. The decision could enable NHS coverage in England for eligible people with type 2 diabetes.
- Clinical Trials & Research accounted for 21 mentions in this edition.

Leading themes:

- Clinical Trials & Research: 70.0% of MSD's coverage (theme index 5.02, net tone +81)
- NHS Access & Pricing: 13.3% of MSD's coverage (theme index 3.51, net tone 0)
- Financial Results & Pipeline: 6.7% of MSD's coverage (theme index 0.58, net tone +50)

Notable positive coverage:

- 26 August 2026, htworld.co.uk: [Personalised vaccine stops cancer returning in trial](https://htworld.co.uk/news/biotech-news/personalised-vaccine-stops-cancer-returning-in-trial-mipo26/). Interim phase-three results suggest that personalised melanoma vaccine intismeran, developed by MSD and Moderna and used with Keytruda, extends cancer-free time. NHS England is preparing for potential adoption pending trial completion, regulatory approval and further NHS assessment.

- [MSD deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=msd&view=deep-dive)
- [MSD PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/msd.pdf)

### Moderna

**Moderna moved from tenth to fifth across an uneven period**

Moderna ranked 5th of 10 by average monthly share of coverage (3.3%) in the Pharma in the UK benchmark for August 2026, with 30 mentions and a net tone of +90.

August reached fifth as stories covered Phase 3 melanoma-vaccine results, the first Lynch-syndrome trial participant and authorisation of an updated UK-made Spikevax booster. August 2026: BBC News reported encouraging early Phase 3 results for Moderna and MSD’s personalised melanoma vaccine used with Keytruda. Moderna and MSD’s personalised melanoma vaccine was reported to have reduced recurrence risk in clinical research, with British patients among those enrolled at UCLH. The article says the treatment could reach the NHS next year if regulators approve it. The Times editorial describes Moderna’s cancer-vaccine trial result as a triumph and argues that ministers should remove barriers to the UK’s life-sciences competitiveness. The article assesses whether UK mRNA manufacturing, NHS cancer-vaccine trial infrastructure and accelerated access routes could support a personalised melanoma vaccine developed by Moderna and MSD. It identifies future MHRA and NICE decisions, NHS genomic capacity and reimbursement as key tests.

Key messages:

- Moderna and MSD’s personalised melanoma vaccine was reported to have reduced recurrence risk in clinical research, with British patients among those enrolled at UCLH. The article says the treatment could reach the NHS next year if regulators approve it.
- The Times editorial describes Moderna’s cancer-vaccine trial result as a triumph and argues that ministers should remove barriers to the UK’s life-sciences competitiveness.
- The article assesses whether UK mRNA manufacturing, NHS cancer-vaccine trial infrastructure and accelerated access routes could support a personalised melanoma vaccine developed by Moderna and MSD. It identifies future MHRA and NICE decisions, NHS genomic capacity and reimbursement as key tests.
- The MHRA authorised Moderna’s XFG-targeted Spikevax COVID-19 booster for people aged six months and over. Doses will be made at Moderna’s Harwell, Oxfordshire site and supplied to the NHS for the 2026/27 vaccination programme.
- Moderna and MSD reported positive preliminary Phase 3 results for their personalised mRNA melanoma vaccine, intismeran, used with Keytruda. UK experts highlighted the implications for cancer-vaccine trials and potential future NHS use, while awaiting full data.

Leading themes:

- Clinical Trials & Research: 70.0% of Moderna's coverage (theme index 5.02, net tone +86)
- NHS Access & Pricing: 6.7% of Moderna's coverage (theme index 1.65, net tone +100)
- M&A & Licensing: 6.7% of Moderna's coverage (theme index 0.32, net tone +100)

Notable positive coverage:

- 20 August 2026, ibtimes.co.uk: [Moderna's Personalised Cancer Vaccine Clears Phase 3: How Soon Could Patients Receive It?](https://www.ibtimes.co.uk/modernas-personalised-cancer-vaccine-clears-phase-3-how-soon-could-patients-receive-it-1815257). Moderna and MSD reported that their personalised cancer vaccine combined with Keytruda met Phase 3 melanoma recurrence and metastasis-free survival endpoints. The article says UK access would require MHRA authorisation and likely a separate NHS cost-effectiveness assessment.
- 20 August 2026, mirror.co.uk: [Skin cancer vaccine slashes risk of dying from the disease - giving hope to thousands](https://www.mirror.co.uk/news/health/skin-cancer-vaccine-breakthrough-jab-37572075.amp). Moderna and MSD’s personalised melanoma vaccine was reported to have reduced recurrence risk in clinical research, with British patients among those enrolled at UCLH. The article says the treatment could reach the NHS next year if regulators approve it.
- 19 August 2026, bbc.co.uk: [Vaccine breakthrough stops cancer returning in trial](https://www.bbc.co.uk/news/articles/c79gpv7v190o). Moderna and MSD said their personalised mRNA melanoma vaccine, used with Keytruda, extended the time patients remained cancer-free in a trial. The treatment would require regulatory approval before it could be available on the NHS.

- [Moderna deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=moderna&view=deep-dive)
- [Moderna PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/moderna.pdf)

### Pfizer

**Pfizer’s visibility swung as safety coverage persisted**

Pfizer ranked 7th of 10 by average monthly share of coverage (1.8%) in the Pharma in the UK benchmark for August 2026, with 16 mentions and a net tone of −12.

In August 2026, Pfizer recorded 16 mentions, 1.8% of cohort coverage and rank #7, with net sentiment of -12. Coverage focused on Medicines Safety, Supply & Patient Use. August 2026: share fell 2.5 percentage points to 1.8% and rank moved from sixth to seventh; Chemistry World covered the 25th anniversary of Pfizer’s green chemistry programme. The article reports that a 90-year-old UK grandmother was the first person to receive the Pfizer Covid-19 vaccine. It concerns the UK vaccine rollout. Pfizer marks 25 years of its green chemistry programme, including sustainable manufacturing improvements for Viagra and Paxlovid. The programme expanded to Pfizer's Sandwich, UK, site and supports the company's net-zero ambitions. A Scottish woman says she has experienced symptoms consistent with a meningioma after long-term use of Pfizer-manufactured Depo-Provera and has been unable to obtain an MRI scan. The article reports wider Scottish legal claims and concerns over warnings about the contraceptive injection's tumour risk.

Key messages:

- The article reports that a 90-year-old UK grandmother was the first person to receive the Pfizer Covid-19 vaccine. It concerns the UK vaccine rollout.
- Pfizer marks 25 years of its green chemistry programme, including sustainable manufacturing improvements for Viagra and Paxlovid. The programme expanded to Pfizer's Sandwich, UK, site and supports the company's net-zero ambitions.
- A Scottish woman says she has experienced symptoms consistent with a meningioma after long-term use of Pfizer-manufactured Depo-Provera and has been unable to obtain an MRI scan. The article reports wider Scottish legal claims and concerns over warnings about the contraceptive injection's tumour risk.
- A Dundee woman who used Pfizer's Depo-Provera contraceptive injection is among Scottish claimants alleging that it caused meningioma brain tumours. Claimants are seeking damages and a UK-wide public inquiry, while Pfizer says it continuously monitors medicine safety.

Leading themes:

- Vaccines & Public Health: 31.3% of Pfizer's coverage (theme index 17.23, net tone +60)
- Medicines Safety, Supply & Patient Use: 31.3% of Pfizer's coverage (theme index 2.87, net tone −100)
- M&A & Licensing: 18.8% of Pfizer's coverage (theme index 0.93, net tone −33)

Notable positive coverage:

- 28 August 2026, guardian.ng: [UK approves Pfizer-BioNTech Covid-19 vaccine for mass inoculation](https://guardian.ng/tv/uk-approves-pfizer-biontech-covid-19-vaccine-for-mass-inoculation/). The UK approved the Pfizer-BioNTech Covid-19 vaccine for mass inoculation.
- 28 August 2026, guardian.ng: [90-year-old UK grandmother first to receive Pfizer Covid vaccine](https://guardian.ng/tv/90-year-old-uk-grandmother-first-to-receive-pfizer-covid-vaccine/). The article reports that a 90-year-old UK grandmother was the first person to receive the Pfizer Covid-19 vaccine. It concerns the UK vaccine rollout.
- 28 August 2026, guardian.ng: [Coronavirus: UK approves Pfizer-BioNTech vaccine, to roll out next week](https://guardian.ng/tv/coronavirus-uk-approves-pfizer-biontech-vaccine-to-roll-out-next-week/). The article reports that the UK approved the Pfizer-BioNTech Covid-19 vaccine and planned to begin its rollout the following week.

Notable negative coverage:

- 19 August 2026, dailyrecord.co.uk: [Depo victim opens up about diagnosis hell after tumour dismissed as Covid](https://www.dailyrecord.co.uk/news/scottish-news/depo-jag-victim-opens-up-37563379). A Scottish woman alleges that long-term use of Pfizer's Depo-Provera contraceptive injection contributed to a meningioma, and is among women pursuing damages against the company. The article reports calls for stronger awareness and a UK-wide inquiry into the medicine's risks.
- 12 August 2026, dailyrecord.co.uk: ['I have brain tumour symptoms after contraceptive jab but i'm being ignored'](https://www.dailyrecord.co.uk/news/scottish-news/i-brain-tumour-symptoms-after-37537602). A Scottish woman says she has experienced symptoms consistent with a meningioma after long-term use of Pfizer-manufactured Depo-Provera and has been unable to obtain an MRI scan. The article reports wider Scottish legal claims and concerns over warnings about the contraceptive injection's tumour risk.
- 7 August 2026, dailyrecord.co.uk: [Woman lost dream job after docs find brain tumours 'caused by contraceptive jab'](https://www.dailyrecord.co.uk/news/scottish-news/woman-lost-dream-job-after-37512247). A Dundee woman who used Pfizer's Depo-Provera contraceptive injection is among Scottish claimants alleging that it caused meningioma brain tumours. Claimants are seeking damages and a UK-wide public inquiry, while Pfizer says it continuously monitors medicine safety.

- [Pfizer deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=pfizer&view=deep-dive)
- [Pfizer PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/pfizer.pdf)

### Roche

**Roche moved among access, research, diagnostics and dealmaking**

Roche ranked 8th of 10 by average monthly share of coverage (1.4%) in the Pharma in the UK benchmark for August 2026, with 13 mentions and a net tone of +69.

August’s share was 1.4%, alongside UK recruitment for the Zenith hypertension trial and a diagnostics partnership with the UK Health Security Agency. Roche and Alnylam are recruiting UK patients into the phase-three Zenith trial of six-monthly hypertension injection zilebesiran, including at more than 50 UK sites. The trial will assess whether the treatment reduces cardiovascular events and could support future regulatory submissions. A financing roundup includes Scotland-based Mironid's £34m Series B raise to support development of therapies for polycystic kidney disease. Roche Venture Fund participated in the investment round. Eli Lilly launched its Foundayo weight-loss pill in the UK for eligible adults. The article also reports US FDA clearance of an Alzheimer's blood test developed by Roche and Eli Lilly. AstraZeneca and Amgen reported that Tezspire met all primary and key secondary endpoints in a phase 3 eosinophilic esophagitis trial, supporting a potential new indication. The article places the result in the competitive inflammatory-disease market, including Sanofi's Dupixent and other anti-TSLP programmes.

Key messages:

- Roche Diagnostics UK has signed an MoU with the UK Health Security Agency to support diagnostics, health equity and pandemic preparedness. The partnership builds on Roche's role in the UK's Covid-19 testing response and UKHSA plans for scalable future outbreak testing.
- Roche and Alnylam are recruiting UK patients into the phase-three Zenith trial of six-monthly hypertension injection zilebesiran, including at more than 50 UK sites. The trial will assess whether the treatment reduces cardiovascular events and could support future regulatory submissions.
- A financing roundup includes Scotland-based Mironid's £34m Series B raise to support development of therapies for polycystic kidney disease. Roche Venture Fund participated in the investment round.
- Eli Lilly launched its Foundayo weight-loss pill in the UK for eligible adults. The article also reports US FDA clearance of an Alzheimer's blood test developed by Roche and Eli Lilly.

Leading themes:

- Drug Approvals & Launches: 38.5% of Roche's coverage (theme index 1.69, net tone +100)
- Clinical Trials & Research: 23.1% of Roche's coverage (theme index 1.47, net tone +33)
- Financial Results & Pipeline: 15.4% of Roche's coverage (theme index 1.36, net tone +50)

Notable positive coverage:

- 27 August 2026, healthcare-digital.com: [Roche and UKHSA Partner to Improve Public Health Resilience](https://healthcare-digital.com/news/roche-and-ukhsa-partner-to-improve-public-health-resilience). Roche Diagnostics UK has signed an MoU with the UK Health Security Agency to support diagnostics, health equity and pandemic preparedness. The partnership builds on Roche's role in the UK's Covid-19 testing response and UKHSA plans for scalable future outbreak testing.
- 3 August 2026, express.co.uk: ['Game-changer' jab given every six months could change lives for millions](https://www.express.co.uk/life-style/health/2235605/high-blood-pressure-treatment-injection-jab). Roche and Alnylam are recruiting UK patients into the phase-three Zenith trial of six-monthly hypertension injection zilebesiran, including at more than 50 UK sites. The trial will assess whether the treatment reduces cardiovascular events and could support future regulatory submissions.

- [Roche deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=roche&view=deep-dive)
- [Roche PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/roche.pdf)

### Novartis

**Patents & Intellectual Property shaped Novartis' media profile during August 2026**

Novartis ranked 9th of 10 by average monthly share of coverage (1.3%) in the Pharma in the UK benchmark for August 2026, with 12 mentions and a net tone of +92.

August's sharp retreat occurred alongside the successful Entresto patent defence, UK approval of Rhapsido and the Check Her Out breast-cancer campaign. In August 2026, Novartis recorded 12 mentions, 1.3% of cohort coverage and rank #9. Novartis UK is supporting the Check Her Out breast-cancer awareness campaign with Breast Cancer Now and football ambassadors Jen Beattie and Millie Bright. The campaign encourages regular breast checking and awareness of recurrence risks. London's High Court upheld Novartis's Entresto patent and supplementary protection certificate, rejecting Accord Healthcare's attempt to invalidate it. The ruling prevents Accord's planned generic product from entering the UK market while the protection remains in force. A global biotech-deals roundup reports Novartis's acquisition of London-based ADC developer Myricx Bio to strengthen its oncology pipeline. It also covers AstraZeneca licensing collaborations and Roche-owned Genentech's small-molecule research deal with Cambridge-based Astex.

Key messages:

- Novartis UK is supporting the Check Her Out breast-cancer awareness campaign with Breast Cancer Now and football ambassadors Jen Beattie and Millie Bright. The campaign encourages regular breast checking and awareness of recurrence risks.
- London's High Court upheld Novartis's Entresto patent and supplementary protection certificate, rejecting Accord Healthcare's attempt to invalidate it. The ruling prevents Accord's planned generic product from entering the UK market while the protection remains in force.
- A global biotech-deals roundup reports Novartis's acquisition of London-based ADC developer Myricx Bio to strengthen its oncology pipeline. It also covers AstraZeneca licensing collaborations and Roche-owned Genentech's small-molecule research deal with Cambridge-based Astex.
- The MHRA approved Novartis Pharmaceuticals UK’s remibrutinib (Rhapsido) for adults with chronic spontaneous urticaria not adequately controlled by antihistamines. The approval followed review of clinical evidence from two studies involving 925 adults and will remain subject to UK safety monitoring.

Leading themes:

- Patents & Intellectual Property: 33.3% of Novartis's coverage (theme index 147.67, net tone +100)
- ESG & Access Campaigning: 16.7% of Novartis's coverage (theme index 147.67, net tone +100)
- Financial Results & Pipeline: 8.3% of Novartis's coverage (theme index 0.73, net tone 0)

Notable positive coverage:

- 17 August 2026, mirror.co.uk: [Jen Beattie praises Arsenal teammates for support during breast cancer battle](https://www.mirror.co.uk/3am/celebrity-news/jen-beattie-praises-arsenal-teammates-37552933). Novartis UK is supporting the Check Her Out breast-cancer awareness campaign with Breast Cancer Now and football ambassadors Jen Beattie and Millie Bright. The campaign encourages regular breast checking and awareness of recurrence risks.
- 17 August 2026, express.co.uk: [Jen Beattie praises Arsenal teammates for support during breast cancer journey](https://www.express.co.uk/celebrity-news/2239789/jen-beattie-praises-arsenal-teammates). Novartis UK is funding the Check Her Out breast-cancer awareness campaign with Breast Cancer Now. Footballers Jen Beattie and Millie Bright are promoting breast awareness and discussion of recurrence risks.
- 13 August 2026, reuters.com: [Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent](https://www.reuters.com/legal/litigation/novartis-defeats-uk-court-bid-invalidate-blockbuster-drug-entresto-patent-2026-08-13/). London's High Court upheld Novartis's Entresto patent and supplementary protection certificate, rejecting Accord Healthcare's attempt to invalidate it. The ruling prevents Accord's planned generic product from entering the UK market while the protection remains in force.

- [Novartis deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=novartis&view=deep-dive)
- [Novartis PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/novartis.pdf)

### Sanofi

**Access breakthroughs punctuated Sanofi’s volatile competitive position**

Sanofi ranked 9th of 10 by average monthly share of coverage (1.3%) in the Pharma in the UK benchmark for August 2026, with 12 mentions and a net tone of −42.

August 2026: manufacturing issues and a late virus-strain change affected Sanofi’s seasonal influenza-vaccine supplies, reported by Dispensing Doctor. NHS England said a supply issue affected Sanofi's Supemtek TIVr influenza vaccine, although sufficient stock remains available for the 2026-27 flu programme. CSL Seqirus is providing alternative vaccine supplies to help address the disruption. Sanofi cancelled deliveries of its recombinant trivalent influenza vaccine after a batch failure, disrupting GP flu-vaccination plans in England. NHS England said alternative suppliers should enable the adult programme to begin as scheduled. Malin Corp reported an interim profit and said it will value contingent consideration linked to UK-based biotech Kymab at nil after Sanofi discontinued amlitelimab development in atopic dermatitis. The investor also received proceeds from Roche's acquisition of Poseida. The article reviews major pharmaceutical companies' Q2 results, patent-expiry risks, AI deployment and obesity-drug competition. It notes Novo Nordisk's planned UK rollout of oral Wegovy while discussing strategic and pipeline developments at Sanofi, AstraZeneca, GSK, Roche, Novartis and Eli Lilly.

Key messages:

- NHS England said a supply issue affected Sanofi's Supemtek TIVr influenza vaccine, although sufficient stock remains available for the 2026-27 flu programme. CSL Seqirus is providing alternative vaccine supplies to help address the disruption.
- Sanofi cancelled deliveries of its recombinant trivalent influenza vaccine after a batch failure, disrupting GP flu-vaccination plans in England. NHS England said alternative suppliers should enable the adult programme to begin as scheduled.
- Malin Corp reported an interim profit and said it will value contingent consideration linked to UK-based biotech Kymab at nil after Sanofi discontinued amlitelimab development in atopic dermatitis. The investor also received proceeds from Roche's acquisition of Poseida.
- Sanofi has told dispensing-doctor customers that manufacturing issues and a late virus-strain change have affected supplies of its seasonal flu vaccines. The reported loss could affect around two million doses ahead of the UK 2026-27 flu programme.

Leading themes:

- Clinical Trials & Research: 33.3% of Sanofi's coverage (theme index 2.14, net tone 0)
- Financial Results & Pipeline: 25.0% of Sanofi's coverage (theme index 2.24, net tone −67)
- Vaccines & Public Health: 25.0% of Sanofi's coverage (theme index 12.31, net tone −100)

Notable negative coverage:

- 25 August 2026, chemistanddruggist.co.uk: [CSL Seqirus providing additional flu vaccines following stock disruption](https://www.chemistanddruggist.co.uk/news/business/csl-seqirus-providing-additional-flu-vaccines-following-stock-disruption-JNOGL442QJET3CVYBI4LOICF5I/). NHS England said a supply issue affected Sanofi's Supemtek TIVr influenza vaccine, although sufficient stock remains available for the 2026-27 flu programme. CSL Seqirus is providing alternative vaccine supplies to help address the disruption.
- 20 August 2026, pulsetoday.co.uk: [Flu vaccine delivery cancellations to cause ‘significant disruption’, GP leaders warn](https://www.pulsetoday.co.uk/news/clinical-areas/respiratory/flu-vaccine-delivery-cancellations-to-cause-significant-disruption-gp-leaders-warn/). Sanofi cancelled deliveries of its recombinant trivalent influenza vaccine after a batch failure, disrupting GP flu-vaccination plans in England. NHS England said alternative suppliers should enable the adult programme to begin as scheduled.
- 26 August 2026, lse.co.uk: [Malin swings to interim profit as finance income rises and costs fall](https://www.lse.co.uk/news/malin-swings-to-interim-profit-as-finance-income-rises-and-costs-fall-0qnqerdo0wkn00o.html). Malin Corp reported an interim profit and said it will value contingent consideration linked to UK-based biotech Kymab at nil after Sanofi discontinued amlitelimab development in atopic dermatitis. The investor also received proceeds from Roche's acquisition of Poseida.

- [Sanofi deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08?entity=sanofi&view=deep-dive)
- [Sanofi PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08/reports/sanofi.pdf)

## Methodology

- **Share of coverage**: an organisation's mentions divided by all mentions of the organisations tracked in the same sector that month, in UK earned media. It is the central measure of media visibility in Omniscan benchmarks. "Average monthly share" is the mean of the monthly shares across the reporting period.
- **Mention**: one article that covers an organisation, classified as positive, neutral or negative in tone. Articles are deduplicated, and an organisation's own websites and passing sponsorship name-checks are excluded, so only earned media counts.
- **Net tone**: positive mentions minus negative mentions, as a percentage of all mentions (range −100 to +100).
- **Themes**: every article is assigned to one of the sector's editorial themes. A theme index above 1 means the organisation is covered on that theme more than its peers are; below 1 means less.
- **Calculation**: every figure is computed directly from the classified articles; narrative summaries are checked against those figures.
- **Sources**: UK national and international, trade and specialist, regional and local, and aggregator and syndication earned media.

## Other Pharma in the UK editions

- [UK pharma media reputation tracker – 2026 year to date](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd.md)
- [UK pharma media reputation tracker – H1 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1.md)
- [UK pharma media reputation tracker – July 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07.md)
- [UK pharma media reputation tracker – September 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-09.md)
- [All Omniscan media benchmarks](https://www.omniscan.ai/benchmarks.md)

## How to cite

Omniscan, "UK pharma media reputation tracker", August 2026 (1 August 2026–31 August 2026), published 1 September 2026. https://www.omniscan.ai/benchmarks/uk-pharma-2026-08